Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Global Lupus Experts Gather For Historic Meeting -- Urgent And Unmet Needs Of Individuals With Lupus Dominate Agenda
The Lupus Foundation of America (LFA) convened an Expert Panel June 1-2 to address the urgent and unmet need for the development and approval of new, safe, effective, and tolerable medications for people with lupus. It has been more than 50 years since the U.S. Food and Drug Administration (FDA) approved a new drug specifically to treat lupus. Discussions during the two-day meeting in Washington, DC focused on how to better conduct studies of potential new lupus treatments, including clinical endpoints, diagnostic tools, background medications, and clinical trial design.
generic viagra online
Purdue-developed Tool Can Get Most Pollution Control For The Money
There may be thousands of things large and small that can be done to better control pollution on even the smallest waterways, and a new tool developed at Purdue University may help sort out how to choose the best ones.
News of the day
Fate Therapeutics To Present Data On Stimulation Of Osteogenic Activity Using Small Molecule Modulators Of Wnt Pathway
Fate Therapeutics, Inc. announced the presentation of data from its research on small molecule modulators of the Wnt pathway for osteo-regeneration at the 7th Annual Meeting of the International Society for Stem Cell Research (ISSCR) in Barcelona, Spain. In its findings, the Company demonstrated that selected Wnt activators induce the differentiation of mesenchymal stem cells to mature, bone-forming osteoblasts. The study highlights the potential for using small molecule Wnt activators as osteogenic agents. Because osteogenic agents stimulate positive bone growth, they may offer an improved course of action in clinical settings ranging from orthopedics to osteoporosis as compared to current medications aimed at preventing bone decay.
Diagnostics

Medtronic And Abbott Laboratories Resolve Global Vascular Patent Disputes

Medtronic, Inc. (NYSE: MDT) announced global resolution of all outstanding intellectual property litigation with Abbott Laboratories. Terms of the agreement stipulate that neither party will sue each other in the field of coronary stent and stent delivery systems for a period of at least 10 years, subject to certain conditions. The agreement includes a $400 million settlement payment to be made to Abbott and also results in a $42 million success payment to evYsio Medical Devices, LLC, as part of a Medtronic sublicense to Abbott of the evYsio stent design technology. In connection with the settlement, Medtronic expects to report in its first quarter financial results a special charge to be calculated in accordance with generally accepted accounting principles. Following the resolution of these disputes with Abbott, Medtronic has now resolved or settled substantially all intellectual property litigation affecting the stent design and stent delivery systems of its bare metal and drug-eluting stent franchise. As a result, Medtronic will now focus more res on efforts to improve health care for patients with vascular disease. Medtronic


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009